261 |
Développement de stratégies de vectorisation pour réduire les effets de l'hypoxie dans les glioblastomes / Development of vectorization strategies to alleviate hypoxia and its effects in glioblastomaAnfray, Clement 06 October 2017 (has links)
L’hypoxie est l’une des principales causes de résistance aux traitements dans les glioblastomes. Des stratégies permettant de lever l’hypoxie ou de limiter ses effets sont de ce fait nécessaires. Ces travaux de thèse s’intéressent à deux stratégies de vectorisation ciblée agissant contre l’hypoxie. La première stratégie vise à lutter contre les effets de l’hypoxie par une approche combinée de vectorisation cellulaire et moléculaire ciblant une protéine à action pro-tumorale : l’érythropoïétine. Des macrophages ont ainsi été modifiés génétiquement pour leur permettre de surexprimer une forme tronquée de récepteur à l’érythropoïétine conduisant à un ralentissement de la croissance d’un modèle de glioblastome. Les constructions moléculaires ont ensuite été modifiées pour rendre la surexpression inductible par l’hypoxie. La deuxième stratégie vise à réoxygéner spécifiquement la tumeur en se basant sur des nanozéolithes vectrices de gaz hyperoxiques. Les résultats montrent que ces nanoparticules microporeuses ne présentent pas d’effets toxiques majeurs in vitro et in vivo. L’incorporation de fer dans les zéolithes augmente significativement la capacité de transport d’O2 et le gadolinium permet leur utilisation comme agent de contraste en imagerie par résonance magnétique. D’autre part, les nanozéolithes vectrices de CO2/O2 s’accumulent spécifiquement dans le tissu tumoral et augmentent localement le volume sanguin et la quantité d’oxygène. Ainsi, les deux approches développées au cours de cette thèse démontrent le potentiel des stratégies ciblées dirigées contre l’hypoxie dans les glioblastomes. / Hypoxia is one of the main causes of resistance to treatments in glioblastoma, the worst primary brain tumor in term of survival. Two targeted vectorization strategies directed against hypoxia are presented in this thesis work. The first strategy was designed to inhibit hypoxia-induced erythropoietin through the use of macrophages. Macrophages were genetically engineered to overexpress a truncated form of the erythropoietin receptor resulting in a decrease in the tumor volume in a hypoxic model of glioblastoma in vivo. Hypoxia-inducible constructs were then developed. The second strategy aimed to use nanozeolites carrying hyperoxic gases as a tool to specifically reoxygenate the tumor. Results show that these microporous nanoparticles have no adverse effects in vitro and in vivo. The incorporation of iron in the zeolites significantly increases their oxygen transport capacity and the gadolinium allows their use as a contrast agent for magnetic resonance imaging. In addition, nanozeolites carrying CO2/O2 accumulate specifically in the tumor tissue and locally increase the blood volume/oxygenation. Thus, the two strategies developed during this thesis demonstrate the potential to fight against hypoxia specifically in glioblastoma.
|
262 |
Suppression of Tumorigenicity by MicroRNA-138 Through Inhibition of EZH2-CDK4/6-pRb-E2F1 Signal Loop in Glioblastoma MultiformeQiu, Shuwei, Huang, Daquan, Yin, Deling, Li, Fangcheng, Li, Xiangping, Kung, Hsiang fu, Peng, Ying 01 October 2013 (has links)
Deregulation of microRNAs (miRNAs) is implicated in tumor progression. We attempt to indentify the tumor suppressive miRNA not only down-regulated in glioblastoma multiforme (GBM) but also potent to inhibit the oncogene EZH2, and then investigate the biological function and pathophysiologic role of the candidate miRNA in GBM. In this study, we show that miRNA-138 is reduced in both GBM clinical specimens and cell lines, and is effective to inhibit EZH2 expression. Moreover, high levels of miR-138 are associated with long overall and progression-free survival of GBM patients from The Cancer Genome Atlas dataset (TCGA) data portal. Ectopic expression of miRNA-138 effectively inhibits GBM cell proliferation in vitro and tumorigenicity in vivo through inducing cell cycles G1/S arrest. Mechanism investigation reveals that miRNA-138 acquires tumor inhibition through directly targeting EZH2, CDK6, E2F2 and E2F3. Moreover, an EZH2-mediated signal loop, EZH2-CDK4/6-pRb-E2F1, is probably involved in GBM tumorigenicity, and this loop can be blocked by miRNA-138. Additionally, miRNA-138 negatively correlates to mRNA levels of EZH2 and CDK6 among GBM clinical samples from both TCGA and our small amount datasets. In conclusion, our data demonstrate a tumor suppressive role of miRNA-138 in GBM tumorigenicity, suggesting a potential application in GBM therapy.
|
263 |
Suppression of Tumorigenicity by MicroRNA-138 Through Inhibition of EZH2-CDK4/6-pRb-E2F1 Signal Loop in Glioblastoma MultiformeQiu, Shuwei, Huang, Daquan, Yin, Deling, Li, Fangcheng, Li, Xiangping, Kung, Hsiang fu, Peng, Ying 01 October 2013 (has links)
Deregulation of microRNAs (miRNAs) is implicated in tumor progression. We attempt to indentify the tumor suppressive miRNA not only down-regulated in glioblastoma multiforme (GBM) but also potent to inhibit the oncogene EZH2, and then investigate the biological function and pathophysiologic role of the candidate miRNA in GBM. In this study, we show that miRNA-138 is reduced in both GBM clinical specimens and cell lines, and is effective to inhibit EZH2 expression. Moreover, high levels of miR-138 are associated with long overall and progression-free survival of GBM patients from The Cancer Genome Atlas dataset (TCGA) data portal. Ectopic expression of miRNA-138 effectively inhibits GBM cell proliferation in vitro and tumorigenicity in vivo through inducing cell cycles G1/S arrest. Mechanism investigation reveals that miRNA-138 acquires tumor inhibition through directly targeting EZH2, CDK6, E2F2 and E2F3. Moreover, an EZH2-mediated signal loop, EZH2-CDK4/6-pRb-E2F1, is probably involved in GBM tumorigenicity, and this loop can be blocked by miRNA-138. Additionally, miRNA-138 negatively correlates to mRNA levels of EZH2 and CDK6 among GBM clinical samples from both TCGA and our small amount datasets. In conclusion, our data demonstrate a tumor suppressive role of miRNA-138 in GBM tumorigenicity, suggesting a potential application in GBM therapy.
|
264 |
Contributions of Angiomotin-Like-1 on Astrocytic Morphology: Potential Roles in Regulating Connexin-43-Based Astrocytic Gap Junctions, Remodeling the Actin Cytoskeleton and Influencing Cellular PolarityDowning, Nicholas Frederick 10 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Glioblastoma is a lethal cancer that arises from support cells in the nervous system and kills around 20,000 people in the United States each year. While much is known about the highly malignant primary glioblastoma, the natural history of lower grade glioma (LGG) is less understood. While the majority of LGGs are initiated by a mutation in isocitrate dehydrogenase, the events leading to their malignant progression into a grade IV tumor are not known. Analysis of primary tumor sample data has revealed that low transcript levels of Angiomotin-like-1 (AmotL1) strongly associate with poor outcomes of patients with these cancers. Follow-up RNA-sequencing of human embryonic astrocytes with AmotL1 silencing revealed the downregulation of many transcripts that encode proteins mediating gap junctions (GJ) between astrocytes, especially connexin-43 (Cx43). Cx43 protein oligomerizes to form functional channels comprising the astrocytic GJ. AmotL1 knockdown through RNA interference decreases Cx43 transcript and protein levels while increasing its distribution to GJs. This suggests increased GJ formation and intercellular communication, as similar localization patterns are observed in differentiated astrocytes. Astrocytes with AmotL1 knockdown also display a pronounced pancake-like morphology, suggesting that the actin cytoskeleton is affected. Imaging reveals that cells with reduced AmotL1 have characteristic losses in both stress fibers and focal actin under the cell body but notable increases in cortical F-actin. Consistent with previous studies, AmotL1 may promote increases in the number and thickness of F-actin fibers. Because actin binding to related angiomotins is inhibited by phosphorylation from the LATs kinases, I define the effects of expressing wildtype AmotL1 versus mutants that mimic or prevent phosphorylation by LATs1/2. Interestingly, expression of AmotL1 S262D in combination with NEDD4-1, a ubiquitin ligase, results in a profound loss of actin stress fibers. Dependence on NEDD4-1 suggests that this phenotype is due to the induced degradation of proteins that promote F-actin, e.g. RhoA. These results directly support a model in which phosphorylated AmotL1 specifically inhibits F-actin formation as opposed to unphosphorylated AmotL1 which is known to promote stress fiber formation. Thus, in addition to regulating polarity and YAP/TAZ transcriptional co-activators, AmotL1 plays major functions in dictating cellular F-actin dynamics. / 2021-01-01
|
265 |
Targetable Multi-Drug Nanoparticles for Treatment of Glioblastoma with Neuroimaging AssessmentSmiley, Shelby B. 05 1900 (has links)
Indiana University-Purdue University Indianapolis (IUPUI) / Glioblastoma (GBM) is a deadly, malignant brain tumor with a poor long-term
prognosis. The current median survival is approximately fifteen to seventeen months
with the standard of care therapy which includes surgery, radiation, and chemotherapy.
An important factor contributing to recurrence of GBM is high resistance of
GBM cancer stem cells (CSCs), for which a systemically delivered single drug approach
will be unlikely to produce a viable cure. Therefore, multi-drug therapies
are needed. Currently, only temozolomide (TMZ), which is a DNA alkylator, affects
overall survival in GBM patients. CSCs regenerate rapidly and over-express a methyl
transferase which overrides the DNA-alkylating mechanism of TMZ, leading to drug
resistance. Idasanutlin (RG7388, R05503781) is a potent, selective MDM2 antagonist
that additively kills GBM CSCs when combined with TMZ. By harnessing the
strengths of nanotechnology, therapy can be combined with diagnostics in a truly theranostic manner for enhancing personalized medicine against GBM. The goal of this
thesis was to develop a multi-drug therapy using multi-functional nanoparticles (NPs)
that preferentially target the GBM CSC subpopulation and provide in vivo preclinical
imaging capability. Polymer-micellar NPs composed of poly(styrene-b-ethylene
oxide) (PS-b-PEO) and poly(lactic-co-glycolic) acid (PLGA) were developed investigating
both single and double emulsion fabrication techniques as well as combinations
of TMZ and RG7388. The NPs were covalently bound to a 15 base-pair CD133 aptamer
in order to target a specific epitope on the CD133 antigen expressed on the
surface of GBM CSC subpopulation. For theranostic functionality, the NPs were also labelled with a positron emission tomography (PET) radiotracer, zirconium-89
(89Zr). The NPs maintained a small size of less than 100 nm, a relatively neutral
charge and exhibited the ability to produce a cytotoxic effect on CSCs. There was a
slight increase in killing with the aptamer-bound NPs compared to those without a
targeting agent. This work has provided a potentially therapeutic option for GBM
specific for CSC targeting and future in vivo biodistribution studies.
|
266 |
Role of reactive oxygen species in Glioblastoma multiforme microsatellite instabilityWilkinson-Busha, Kortney Lynnette 30 April 2011 (has links)
Glioblastoma multiforme (GBM) is an extremely aggressive and almost always fatal brain tumor. GBM literature indicates defective mismatch repair (MMR) mechanisms are not involved in GBM tumorigenesis as in other tumors, and instigating mechanisms of GBM tumorigenesis remain unclear. GBM and neural progenitor (NPR) cells were exposed to three concentrations of H2O2 (0, 0.5, and 1.0 μM), cultured, and then harvested 0, 2, 4, and 6 days post-exposure; DNA from cells was amplified with microsatellite primers, investigating whether or not H2O2 exposure affected microsatellite instability (MSI) in target sequences. Three out of six markers showed significant MSI in the H2O2-exposed NPR cells. Our results suggest H2O2, which generates reactive oxygen species (ROS), correlated with MSI accumulation that occurred in NPR cells in specific DNA regions. Thus, gene expression analysis to assess normal and abnormal gene expression of GBM and NPR cellss is warranted.
|
267 |
The role of tissue factor in the progression and angiogenesis of malignant glioma /Magnus, Nathalie. January 2008 (has links)
No description available.
|
268 |
The paracrine effect of normoxic and hypoxic cancer secretions on blood-brain barrier endothelial cellsRado, Mariam Abobaker. M. January 2022 (has links)
>Magister Scientiae - MSc / Cancer is the most common leading cause of death worldwide. Glioblastoma and breast cancer are the most aggressive solid tumour. The survival rate of these tumours depends on their ability to progress and spread. These cancers use their high proliferative capabilities for survival, increasing their malignancies. Glioblastoma is considered the most aggressive tumour initiated in the brain, whereas breast cancer is the most common metastatic cancer in the brain, both types of cancer are known as high infiltrated cancer and their invasiveness due to their capability to release factors that can alter the neighbouring cells to facilitate their progression.
|
269 |
Affinity-based Delivery and Reloading of Doxorubicin For Treatment of Glioblastoma MultiformeFu, Andrew Song 23 August 2013 (has links)
No description available.
|
270 |
Metabolic Regulation in Glioblastoma and its Association with Sex-Specific SurvivalTroike, Katie 26 August 2022 (has links)
No description available.
|
Page generated in 0.0628 seconds